Chairman of the Board
Simon then became the CEO of the embryonic start-up company, DNA Research Innovations Ltd (‘DRI’), growing the company for four years which was acquired by the Invitrogen Corporation Inc for $65 million in 2004. After a period with Invitrogen Simon joined Fusion Antibodies in 2006 as the CEO and in 2011 moved to his current Chairman role. During that period he was also the Executive Chairman of Scottish based Lab 901 where he completed several rounds of funding and sold the business in 2011 to Agilent Technologies Inc. He is also currently the CEO of the VC backed diagnostic Company Biofortuna Ltd.